News | March 30, 2026
Eli Lilly trial shows combo therapy dramatically improves psoriatic arthritis, obesity outcomes
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The presentations underscore the company’s deep expertise in dermatology and immunology
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
The campaign highlights a straightforward, achievable approach to health, proving that supporting your wellness doesn’t have to be complicated
Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
Since launching, the hospital has performed over 40 intestinal transplants, including 21 in 2025 alone
Subscribe To Our Newsletter & Stay Updated
